Printer Friendly

IMMUCELL SELLS STOCK TO CAMBRIDGE BIOTECH CORPORATION

 IMMUCELL SELLS STOCK TO CAMBRIDGE BIOTECH CORPORATION
 WORCESTER, Mass., Aug. 27 /PRNewswire/ -- Cambridge Biotech Corporation (NASDAQ: CBCX) today announced that ImmuCell Corporation (NASDAQ: ICCC) has closed the stock purchase and option transaction with CBC, allowing CBC to acquire a 15 percent stake in ImmuCell through a purchase of common stock and granting CBC two options which could allow CBC to acquire an additional interest in ImmuCell's common stock at later dates. Details were released on July 23.
 ImmuCell Corporation is a biotech company that develops, manufactures and markets antibody-based disease prevention products for both human and animal health-care applications.
 Cambridge Biotech Corporation is a leader in the development of recombinant technology and a major producer of viral diagnostic screening and confirmatory products. The company also develops adjuvants and monoclonal antibodies as the basis for diagnostics, vaccine and therapeutic products for humans and animals.
 -0- 8/27/92
 /CONTACT: Peter P. Hartman, vice president-finance and CFO of Cambridge Biotech, 508-797-5777/
 (CBCX ICCC) CO: Cambridge Biotech Corporation; ImmuCell Corporation ST: Massachusetts IN: MTC SU: TNM


CN -- NE002 -- 3769 08/27/92 08:15 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 27, 1992
Words:182
Previous Article:PINKERTON NAMES OLSTEN EXECUTIVE TO NEW POST
Next Article:ARBOR DRUGS, INC. DECLARES QUARTERLY CASH DIVIDEND
Topics:


Related Articles
CAMBRIDGE BIOTECH GRANTS SUBLICENSE TO GENENTECH FOR DEVELOPMENT OF AIDS VACCINE
CAMBRIDGE BIOTECH CORPORATION SIGNS INTENT TO ACQUIRE MINORITY STAKE IN IMMUCELL CORPORATION
CAMBRIDGE BIOTECH ENTERS INTO DEFINITIVE AGREEMENT FOR PURCHASE OF IMMUCELL STOCK; FORMS VENTURE WITH BIONEBRASKA, INC., R&C ENTERPRISES
CAMBRIDGE BIOTECH CORPORATION ACQUIRES RIGHTS TO DYNAGEN'S RAPID ANTIBODY TESTS FOR TUBERCULOSIS AND MYCOBACTERIA
RESULTS OF HUMAN PHASE I TRIAL OF CAMBRIDGE BIOTECH CORPORATION'S STIMULON ADJUVANT REPORTED
CAMBRIDGE BIOTECH REPORTS 1992 RESULTS
CAMBRIDGE BIOTECH LICENSES ITS STIMULON ADJUVANT TO AMERICAN CYANAMID
CAMBRIDGE BIOTECH CORPORATION'S STIMULON ADJUVANT IN PHASE I TRIAL WITH GENENTECH HIV-1 VACCINE
CAMBRIDGE BIOTECH CORPORATION ANNOUNCES COMPLETION OF SALE OF IRISH SUBSIDIARY
HEARING SET FOR JULY 15, 1996 ON CONFIRMATION OF CAMBRIDGE BIOTECH'S PLAN OF REORGANIZATION

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters